# CUX1

Source: https://onco.cc/targets/cux1/  
OnCo record `cux1` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CUX1 (Homeobox protein cut-like 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Skin cancer, Leukaemia, Breast cancer and 5 more.

## Summary

Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III. Also involved in the control of synaptogenesis.

Open Targets scores its association with cancer at 0.82 (direct and indirect evidence; datatypes affected pathway 0.95, literature 0.96, genetic association 0.67, somatic mutation 0.88, animal model 0.69). IntOGen calls it a driver in 7 cohorts (2 activating, 5 loss-of-function), covering Invasive Breast Carcinoma, Glioblastoma, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Melanoma, Pancreatic Adenocarcinoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: cut like homeobox 1; Homeobox protein cut-like 1; CDP1; Clox; CDP/Cut; CDP/Cux; Cux/CDP; GOLIM6; CUTL1
- Tags: cancer-genes-wave
- Symbol: CUX1
- Class: transcription
- Biology: Transcription factor involved in the control of neuronal differentiation in the brain. Regulates dendrite development and branching, and dendritic spine formation in cortical layers II-III. Also involved in the control of synaptogenesis. In addition, it has probably a broad role in mammalian development as a repressor of developmentally regulated gene expression. May act by preventing binding of positively-activing CCAAT factors to promoters. Component of nf-munr repressor; binds to the matrix attachment regions (MARs) (5' and 3') of the immunoglobulin heavy chain enhancer. Location: Nucleus (UniProt). Locus 7q22.1 (HGNC).
- Where found: Skin cancer: Open Targets association 0.67 with skin cancer (MONDO_0002898); Leukaemia: Open Targets association 0.66 with leukaemia (MONDO_0005059); Breast cancer: Open Targets association 0.66 with breast cancer (MONDO_0007254); IntOGen driver in 1 cohort (BRCA); Non-Hodgkin lymphoma: Open Targets association 0.58 with non-Hodgkin lymphoma (MONDO_0018908); Pancreatic ductal adenocarcinoma: IntOGen driver in 1 cohort (PAAD); Thyroid cancer: IntOGen driver in 1 cohort (WDTC)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 2 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 5 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:2557: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2557
- UniProt P39880: https://www.uniprot.org/uniprotkb/P39880/entry
- NCBI Gene 1523: https://www.ncbi.nlm.nih.gov/gene/1523
- Ensembl ENSG00000257923: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000257923

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Leukaemia (all types)](https://onco.cc/cancers/leukaemia/), [Lung cancer (all types)](https://onco.cc/cancers/lung-cancer/), [Myeloproliferative neoplasms (PV, ET, myelofibrosis)](https://onco.cc/cancers/myeloproliferative-neoplasms/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/), [Thyroid cancer](https://onco.cc/cancers/thyroid/)

---
JSON: https://onco.cc/api/v1/entities/cux1.json